-
Electronic (PDF)
-
Site License
-
Enterprisewide
Uterine Fibroids - Pipeline Review, H2 2011
Global Markets Direct, October 2011, Pages: 51
Uterine Fibroids - Pipeline Review, H2 2011
Summary
Global Markets Direct’s, 'Uterine Fibroids - Pipeline Review, H2 2011', provides an overview of the Uterine Fibroids therapeutic pipeline. This report provides information on the therapeutic development for Uterine Fibroids, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Fibroids. 'Uterine Fibroids - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Uterine Fibroids.
- A review of the Uterine Fibroids products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Uterine Fibroids pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Uterine Fibroids.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Uterine Fibroids pipeline depth and focus of Uterine Fibroids therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uterine Fibroids Overview
Therapeutics Development
An Overview of Pipeline Products for Uterine Fibroids
Uterine Fibroids Therapeutics under Development by Companies
Uterine Fibroids Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Uterine Fibroids Therapeutics - Products under Development by Companies
Uterine Fibroids Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Uterine Fibroids Therapeutics Development
Takeda Pharmaceutical Company Limited
Kissei Pharmaceutical Co., Ltd.
Pfizer Inc.
Columbia Laboratories Inc.
Repros Therapeutics Inc.
HRA Pharma, SA
Uterine Fibroids - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
TAK-385 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRA-027 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proellex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaginal Testosterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UPA-UF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Femara - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mifepristone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CDB-2914 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mifepristone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mifepristone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KLH-2109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Uterine Fibroids Therapeutics – Drug Profile Updates
Uterine Fibroids Therapeutics - Discontinued Products
Uterine Fibroids - Featured News
Sep 13, 2011: Neurocrine Biosciences Starts Phase II Study Of Elagolix In Uterine Fibroids
Sep 08, 2011: Repros To Submit IND For Vaginal Delivery Of Proellex For Fibroid De-bulking And Symptom Elimination
Mar 15, 2011: Repros Therapeutics Reports Results From Completed 1mg Dose Cohort In Low Dose Proellex Study
Dec 27, 2010: Repros Completes Preclinical Studies Of Proellex
Dec 16, 2010: Repros Prepares To Begin Dosing In Second Cohort In Low Dose Proellex Study
Jul 22, 2010: Repros Receives Investigational Review Board Approval To Commence Low Dose For Proellex Study At ICON Site
Jun 11, 2010: FDA Lifts Full Clinical Hold On Repros' Proellex
Jun 03, 2010: PregLem Announces Positive Phase III Results For Esmya
May 21, 2010: HRA Pharma’s Partner Preglem Announces Positive Phase III Results For Ulipristal Acetate In The Treatment Of Uterine Fibroids
May 18, 2010: PregLem Announces Positive Phase III Results Of Esmya For Treatment Of Uterine Fibroids
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
